Wall Street investment bank Evercore ISI (EVR) is pounding the table on Nvidia (NVDA) stock ahead of the chipmaker’s upcoming ...

Evercore ISI analyst Liisa Bayko upgraded Crispr Therapeutics (CRSP) to Outperform from In Line with a price target of $99, up from $60.

Evercore ISI analysts upgraded CRISPR Therapeutics stock from an In Line to an Outperform rating and increased the price target significantly to $99 from the previous $60. The upgrade comes as ...

Fintel reports that on February 13, 2025, Evercore ISI Group downgraded their outlook for Trade Desk (NasdaqGM:TTD) from ...

Confluent (NASDAQ:CFLT – Get Free Report) had its target price upped by Evercore ISI from $32.00 to $40.00 in a report ...

The Carlyle Group (NASDAQ:CG – Get Free Report) had its price target hoisted by analysts at Evercore ISI from $51.00 to $52.00 in a report issued on Wednesday,Benzinga reports. The firm presently has ...

Rich Ross, head of technical analysis at Evercore ISI, said that a breakout to an all-time high in the S&P 500 ( SP500 ), ( ...

In the lead-up to Nvidia Inc.’s NVDA forthcoming earnings report after market close on Feb.26, Evercore ISI suggests that it is a good buying opportunity amid strong fundamentals. What Happened: In a ...

Evercore ISI lifted Juniper Networks (NYSE:JNPR) stock to Outperform from In-Line on Tuesday while maintaining a $40 price target.

Fears that DeepSeek may be moving AI workloads from Nvidia's GPUs to Application-Specific Integrated Circuits combined with possible delays in the Blackwell chip release have caused lags in Nvidia ...